[5 -fluoropyrimidines for treatment of biliary tract cancers].
Morizane
Chigusa
C
Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital.
Okusaka
Takuji
T
Ueno
Hideki
H
Ikeda
Masafumi
M
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001661:Biliary Tract Neoplasms / Q000188:drug therapy*; D000069287:Capecitabine; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004338:Drug Combinations; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D010094:Oxonic Acid / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
D000970:Antineoplastic Agents; D004338:Drug Combinations; D011725:Pyridines; D011743:Pyrimidines; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D014498:Uracil; D010094:Oxonic Acid; C029269:5-fluoropyrimidine; D000069287:Capecitabine; D005472:Fluorouracil